. Author manuscript; available in PMC: 2018 Jul 20.

Published in final edited form as: Am Soc Clin Oncol Educ Book. 2016;35:e72–e78. doi: 10.14694/EDBK_160391

TABLE 3.

Rate of Deleterious Mutations and VUS Reported in Multigene Testing Associated with Colorectal Cancer

Publication	No. Patients	Panel Tested	LS Genes (MLH1, MSH2, MSH6, PMS2, EPCAM) Mutations Detected (%)	Non-LS Genes Mutations Detected (%)	VUS Rate (%)
LaDuca et al⁴³	557	Ambry Genetics	4.5%: MSH (7), MLH1 (7), PMS2 (6), MSH (5)	4.7% (26): APC (6), CHEK2 (6), MUTYH biallelic (6), SMAD4 (4), PTEN (3), CDH1 (1), STK11 (1), TP53 (1)	15.1% (84)
Yurgelun et al⁴⁴	1,260	Myriad MyRisk Hereditary Cancer	9.5%	3.8% (48): BRCA1/2 (15), APC biallelic MUTYH, PTEN, STK11, ATM, BARD1, BRIP1, CHEK2, NBN, PALB2, and RAD51C	44%

Abbreviations: LS, Lynch syndrome; VUS, variants of uncertain significance.